Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 5/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | RHOC | P08134 | 1/20 | 0.51 |
| ▸ | RHOA | P61586 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22025349 | 0.92 | BRAF (0.58) | BRAFHDAC3HDAC8HDAC6CSF1R | |
| SCHEMBL22024518 | 0.90 | BRAF (0.69) | BRAFCSF1RKITP2RX1GAA | |
| SCHEMBL22024983 | 0.89 | P2RX1 (0.54) | HDAC3HDAC8HDAC6CSF1RKIT | |
| SCHEMBL22024681 | 0.83 | KIT (0.68) | BRAFCSF1RKITMEN1HTT | |
| SCHEMBL1358516 | 0.82 | BRAF (0.56) | BRAFHDAC3HDAC8HDAC6CSF1R | |
| SCHEMBL1358527 | 0.80 | HDAC3 (0.58) | BRAFHDAC3HDAC8HDAC6CSF1R | |
| SCHEMBL17316210 | 0.80 | HDAC3 (0.58) | BRAFHDAC3HDAC8HDAC6CSF1R | |
| SCHEMBL22025430 | 0.80 | MEN1 (0.59) | BRAFMEN1HTTRAB9AKMT2A | |
| Nitric Acid SCHEMBL1358553 | 0.77 | BRAF (0.51) | BRAFHDAC3HDAC8HDAC6CSF1R | |
| SCHEMBL19500731 | 0.77 | HDAC3 (0.54) | BRAFHDAC3HDAC8HDAC6CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | BRAF 65/4885HDAC3 1255/4885HDAC8 573/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | BRAF 65/4885HDAC3 1255/4885HDAC8 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.